MAP2K7 and colorectal carcinoma: To further explore this phenomenon, we examined sensitivity to the same BRAF/MEK/ERK inhibitors in a panel of BRAFV600-mutant cell lines, 9 CRC and 37 melanoma.37 Consistent with clinical experience, the majority of melanoma cell lines were sensitive to BRAF and MEK (as well as ERK) inhibition and a fraction highly resistant, while the pattern is reversed in CRC cells (Fig. 3d).